Stock BMY BRISTOL-MYERS SQUIBB COMPANY
Add to a list
To use this feature you must be a member
Log inSign up
PDF Report : Bristol-Myers Squibb Company

Press Releases Bristol-Myers Squibb Company

Equities

BMY

US1101221083

Real-time Estimate Cboe BZX
Other stock markets
 10:32:25 2023-12-08 am EST 		Intraday chart for Bristol-Myers Squibb Company 5-day change 1st Jan Change
50.4 USD +0.47% +0.16% -30.26%
Dec. 07 Global markets live: AbbVie, McDonald's, Apple, AMD, Alphabet...
Dec. 07 Are rate cuts are coming early next year?

Press Releases

Search
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Bristol Myers Squibb Announces Phase 3 CheckMate -8HW Trial Evaluating Opdivo Plus Yervoy Compared to Chemotherapy in Microsatellite Instability-High or Mismatch Repair Deficient Metastatic Colorectal Cancer Meets Primary
AQ
Bristol Myers Squibb Announces Phase 3 CheckMate -8HW Trial Evaluating Opdivo (nivolumab) Plus Yervoy (ipilimumab) Compared to Chemotherapy in Microsatellite Instability–High or Mismatch Repair Deficient Metastatic Colorectal Cancer Meets Primary...
BU
Bristol Myers Squibb Announces Additional $3 Billion Share Repurchase Authorization
BU
Bristol Myers Squibb Announces Dividend Increase
BU
Bristol Myers Squibb : Abecma® Becomes First CAR T Approved for Use in Earlier Lines of Therapy for Patients with Relapsed or Refractory Multiple Myeloma in Japan
PU
U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb's Application for Opdivo in Combination with Cisplatin-Based Chemotherapy for the First-Line Treatment of Adult Patients
AQ
U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb’s Application for Opdivo (nivolumab) in Combination with Cisplatin-Based Chemotherapy for the First-Line Treatment of Adult Patients with Unresectable or Metastatic...
BU
Avidity Biosciences Announces Expansion of Cardiovascular Collaboration with Bristol Myers Squibb for up to Five Targets Utilizing Avidity's Proprietary AOC Platform Technology
AQ
Avidity Biosciences Announces Expansion of Cardiovascular Collaboration with Bristol Myers Squibb for up to Five Targets Utilizing Avidity's Proprietary AOC™ Platform Technology
PR
Bristol Myers Squibb and 2seventy bio Provide Update on U.S. FDA Review of sBLA for Abecma in Earlier Lines of Therapy for Triple-Class Exposed Relapsed or Refractory Multiple Myeloma
AQ
Microsoft, Palantir rise; Bristol-Myers, Kohl's fall, Monday, 11/20/2023
AQ
Bristol Myers Squibb and 2seventy bio Provide Update on U.S. FDA Review of sBLA for Abecma (idecabtagene vicleucel) in Earlier Lines of Therapy for Triple-Class Exposed Relapsed or Refractory Multiple Myeloma
BU
Bristol Myers Squibb - U.S. Food and Drug Administration Approves Augtyro, a Next-Generation Tyrosine Kinase Inhibitor, for the Treatment of Locally Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer
AQ
U.S. Food and Drug Administration Approves Augtyro™ (repotrectinib), a Next-Generation Tyrosine Kinase Inhibitor (TKI), for the Treatment of Locally Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer (NSCLC)
BU
Medullary Thyroid Cancer Pipeline, Clinical Trials Studies, Emerging Drugs, Mergers and Acquisition, Licensing, Agreements & Collaborations, and Latest News 2023 (Updated)
AQ
Bristol Myers Squibb to Participate in the 2023 Jefferies London Healthcare Conference
BU
U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb’s Application for Breyanzi (lisocabtagene maraleucel) for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)
BU
Bristol Myers Squibb to Present Data from Innovative Cardiovascular Portfolio at the American Heart Association Scientific Sessions 2023
BU
Bristol Myers Squibb’s First Disclosures and New Data at ASH 2023 Highlight Company’s Leadership and Progress in Cell Therapy, Targeted Protein Degradation and Novel Approaches in Hematology
BU
Bristol Myers Squibb to Participate in the 2023 UBS BioPharma Conference
BU
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages MarketScreener Editorial Features MarketScreener Strategies

Filters

Announcement Date

Since

Until

  1. Stock
  2. Equities
  3. Stock Bristol-Myers Squibb Company - Nyse
  4. News Bristol-Myers Squibb Company
  5. Press Releases
The best tools reserved for subscribers to boost the performance of your investments!
Optimize my profits
fermer